Cargando…

Network pharmacology-based research on the effect of angelicin on osteosarcoma and the underlying mechanism

To explore the antitumor effects of angelicin on osteosarcoma and the underlying mechanism. We aimed to elucidate the mechanism by network pharmacology, molecular docking, and in vitro experiments. We analyzed a PPI network of potential angelicin targets in the treatment of osteosarcoma and identifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yafang, Wei, Junqiang, Kong, Lingwei, Song, Mingze, Zhang, Yange, Xiao, Xiangyu, Cao, Haiying, Li, Zhehong, Yang, Ning, Jin, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292874/
https://www.ncbi.nlm.nih.gov/pubmed/37301545
http://dx.doi.org/10.18632/aging.204786
_version_ 1785062901264941056
author Zhang, Yafang
Wei, Junqiang
Kong, Lingwei
Song, Mingze
Zhang, Yange
Xiao, Xiangyu
Cao, Haiying
Li, Zhehong
Yang, Ning
Jin, Yu
author_facet Zhang, Yafang
Wei, Junqiang
Kong, Lingwei
Song, Mingze
Zhang, Yange
Xiao, Xiangyu
Cao, Haiying
Li, Zhehong
Yang, Ning
Jin, Yu
author_sort Zhang, Yafang
collection PubMed
description To explore the antitumor effects of angelicin on osteosarcoma and the underlying mechanism. We aimed to elucidate the mechanism by network pharmacology, molecular docking, and in vitro experiments. We analyzed a PPI network of potential angelicin targets in the treatment of osteosarcoma and identified hub targets. We systematically performed GO and KEGG enrichment analyses of the potential targets of angelicin, and we predicted it function in osteosarcoma treatment and the underlying molecular mechanism. Through molecular docking, the interactions between hub targets and angelicin were simulated, and then, the hub targets of angelicin were identified. Based on these results, we validated the effects of angelicin on osteosarcoma cells by conducting in vitro experiments. The PPI network analysis of potential therapeutic targets identified four apoptosis-related hub targets, namely, BCL-2, Casp9, BAX and BIRC 2. GO and KEGG enrichment analyses demonstrated that angelicin regulates osteosarcoma cell apoptosis. Molecular docking results indicated that angelicin can freely bind to the hub targets listed above. In vitro experiments showed that angelicin promoted osteosarcoma cell apoptosis in a dose-dependent manner and inhibited osteosarcoma cell migration and proliferation in a time- and dose-dependent manner. The RT-PCR results showed that angelicin simultaneously promoted the mRNA expression of Bcl-2 and Casp9 and inhibited the mRNA expression of BAX and BIRC 2. Angelicin promotes osteosarcoma cell apoptosis and inhibits osteosarcoma cell proliferation and migration by activating a signaling network that is composed of hub targets that link multiple signaling pathways. Angelicin could become an alternative drug for the treatment of osteosarcoma.
format Online
Article
Text
id pubmed-10292874
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-102928742023-06-27 Network pharmacology-based research on the effect of angelicin on osteosarcoma and the underlying mechanism Zhang, Yafang Wei, Junqiang Kong, Lingwei Song, Mingze Zhang, Yange Xiao, Xiangyu Cao, Haiying Li, Zhehong Yang, Ning Jin, Yu Aging (Albany NY) Research Paper To explore the antitumor effects of angelicin on osteosarcoma and the underlying mechanism. We aimed to elucidate the mechanism by network pharmacology, molecular docking, and in vitro experiments. We analyzed a PPI network of potential angelicin targets in the treatment of osteosarcoma and identified hub targets. We systematically performed GO and KEGG enrichment analyses of the potential targets of angelicin, and we predicted it function in osteosarcoma treatment and the underlying molecular mechanism. Through molecular docking, the interactions between hub targets and angelicin were simulated, and then, the hub targets of angelicin were identified. Based on these results, we validated the effects of angelicin on osteosarcoma cells by conducting in vitro experiments. The PPI network analysis of potential therapeutic targets identified four apoptosis-related hub targets, namely, BCL-2, Casp9, BAX and BIRC 2. GO and KEGG enrichment analyses demonstrated that angelicin regulates osteosarcoma cell apoptosis. Molecular docking results indicated that angelicin can freely bind to the hub targets listed above. In vitro experiments showed that angelicin promoted osteosarcoma cell apoptosis in a dose-dependent manner and inhibited osteosarcoma cell migration and proliferation in a time- and dose-dependent manner. The RT-PCR results showed that angelicin simultaneously promoted the mRNA expression of Bcl-2 and Casp9 and inhibited the mRNA expression of BAX and BIRC 2. Angelicin promotes osteosarcoma cell apoptosis and inhibits osteosarcoma cell proliferation and migration by activating a signaling network that is composed of hub targets that link multiple signaling pathways. Angelicin could become an alternative drug for the treatment of osteosarcoma. Impact Journals 2023-06-10 /pmc/articles/PMC10292874/ /pubmed/37301545 http://dx.doi.org/10.18632/aging.204786 Text en Copyright: © 2023 Zhang et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Zhang, Yafang
Wei, Junqiang
Kong, Lingwei
Song, Mingze
Zhang, Yange
Xiao, Xiangyu
Cao, Haiying
Li, Zhehong
Yang, Ning
Jin, Yu
Network pharmacology-based research on the effect of angelicin on osteosarcoma and the underlying mechanism
title Network pharmacology-based research on the effect of angelicin on osteosarcoma and the underlying mechanism
title_full Network pharmacology-based research on the effect of angelicin on osteosarcoma and the underlying mechanism
title_fullStr Network pharmacology-based research on the effect of angelicin on osteosarcoma and the underlying mechanism
title_full_unstemmed Network pharmacology-based research on the effect of angelicin on osteosarcoma and the underlying mechanism
title_short Network pharmacology-based research on the effect of angelicin on osteosarcoma and the underlying mechanism
title_sort network pharmacology-based research on the effect of angelicin on osteosarcoma and the underlying mechanism
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292874/
https://www.ncbi.nlm.nih.gov/pubmed/37301545
http://dx.doi.org/10.18632/aging.204786
work_keys_str_mv AT zhangyafang networkpharmacologybasedresearchontheeffectofangelicinonosteosarcomaandtheunderlyingmechanism
AT weijunqiang networkpharmacologybasedresearchontheeffectofangelicinonosteosarcomaandtheunderlyingmechanism
AT konglingwei networkpharmacologybasedresearchontheeffectofangelicinonosteosarcomaandtheunderlyingmechanism
AT songmingze networkpharmacologybasedresearchontheeffectofangelicinonosteosarcomaandtheunderlyingmechanism
AT zhangyange networkpharmacologybasedresearchontheeffectofangelicinonosteosarcomaandtheunderlyingmechanism
AT xiaoxiangyu networkpharmacologybasedresearchontheeffectofangelicinonosteosarcomaandtheunderlyingmechanism
AT caohaiying networkpharmacologybasedresearchontheeffectofangelicinonosteosarcomaandtheunderlyingmechanism
AT lizhehong networkpharmacologybasedresearchontheeffectofangelicinonosteosarcomaandtheunderlyingmechanism
AT yangning networkpharmacologybasedresearchontheeffectofangelicinonosteosarcomaandtheunderlyingmechanism
AT jinyu networkpharmacologybasedresearchontheeffectofangelicinonosteosarcomaandtheunderlyingmechanism